What are the take-home messages from ESC 22 and what are the implications for practice?
In this short wrap-up video of ESC 22, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) review the most impactful hot line and late-breaking trials of ESC Congress 2022. 

Trials covered in detail include:

On clinical judgement after PCI
00:35:27:REVIVED-BCIS2: Study of Efficacy and Safety of Percutaneous Coronary Intervention to Improve Survival in Heart Failure 
05:18:42: FRAME-AMI: FFR Versus Angiography-Guided Strategy for Management of AMI With Multivessel Disease 
08:02:01: PREFFIR: Prediction of Recurrent Events With 18F-Fluoride
09:33:46: POST-PCI: Routine Stress Testing after High-Risk PCI

On pharmacotherapy
12:13:04: DELIVER: Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure
13:46:03: ADVOR: Acetazolamide in Decompensated Heart Failure With Volume OveRload 
17:58:31: REDUCE-IT: A Study of AMR101 to Evaluate Its Ability to Reduce Cardiovascular Events in High-Risk Patients With Hypertriglyceridemia and on Statin 
19:09:06: INVICTUS: INVestIgation of rheumatiC AF Treatment Using Vitamin K Antagonists, Rivaroxaban or Aspirin Studies, Non-Inferiority
21:38:23: PACIFIC-AMI: Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack 
24:08:30: SECURE: Polypill Strategy in Secondary Cardiovascular Prevention

On structural heart
25:56:39: COAPT: Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation 

On digital health
29:28:17: AI-ENHANCED: Enhanced Diagnosis of Severe Aortic Stenosis Using Artificial Intelligence: A Proof-of-Concept Study of 530,871 Echocardiograms 
31:04:18: eBRAVE-AF: eHealth-based Bavarian Alternative Detection of Atrial Fibrillation: A Randomized Controlled Trial

For more ESC coverage browse our ESC Late-breaking Science Collection.